Key result
Echocardiographic screening identifies a significant burden of clinically silent, mild RHD preceding advanced disease.
Why the study?
Echocardiographic screening has revealed a high burden of clinically silent, mild rheumatic heart disease, altering understanding of its natural history and pathways to advanced disease.
Design
Viewpoint
Recognizing early RHD as an intermediate stage provides a critical window for secondary antibiotic prophylaxis and offers a practical endpoint for Streptococcus pyogenes vaccine trials.
Rheumatic heart disease is a major cause of premature cardiovascular morbidity and mortality globally.Over the past decade, echocardiographic screening has changed our understanding of the natural history of RHD, revealing a high burden of clinically silent, mild RHD among people who cannot recall a history of preceding acute rheumatic fever.This viewpoint outlines the evidence that this earliest form of rheumatic heart disease, only detectable through echocardiographic screening, is an intermediate stage that many, but not all, individuals may pass through on the pathway to advanced rheumatic heart disease.This shift in understanding has important clinical and research implications, including introducing a new and more pragmatic target for Streptococcus pyogenes vaccine trials for the indication of rheumatic heart disease prevention.
No takes yet. Share an insight, caveat, or question.
Marangou et al. (2026) studied this question. Echocardiographic screening identifies a significant burden of clinically silent, mild rheumatic heart disease as an intermediate stage before advanced disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: